President-elect Donald Trump has announced the nomination of Robert F. Kennedy Jr. to lead the Department of Health and Human Services (HHS), a move that signals a potential shift in federal health priorities. In a statement, Trump said Kennedy would focus on ending the 'chronic disease epidemic' and addressing issues related to food safety and transparency in the pharmaceutical industry. Kennedy, a former environmental lawyer and independent presidential candidate, has long advocated for major reforms within agencies like the FDA and CDC. While supporters view the nomination as an opportunity to challenge the status quo and improve public health outcomes, the choice has met with immediate pushback from many in the medical and scientific communities. Critics point to Kennedy's past statements regarding vaccine safety and public health mandates as cause for concern, warning of potential impacts on national immunization programs. Market analysts noted a drop in healthcare and pharmaceutical stocks following the news, reflecting investor uncertainty. The nomination now moves to the Senate for a confirmation process that is expected to be highly scrutinized by both parties.